HIGHLIGHTS
- who: amuradyan from the Military Medical University have published the article: THE EFFICACY AND SAFETY OF THREE 30-DAY COURSES OF ALBENDAZOLE IN PATIENTS WITH NEUROCYSTICERCOSIS, in the Journal: (JOURNAL)
- what: This study was carried out to investigate the efficacy and safety of a prolonged regime of albendazole in patients with NCC. This difference in the efficacy could be due to the longer duration of therapy (90 days) in the study compared to previously cited studies (7-28 days) .
- how: The results are supported by another observation and suggest that an extension of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.